The American Journal of Managed Care45m
Can a New Therapeutic Combo Address a Rare Form of RCC?
Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a ...
AFP23h
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase ...